Regeneron turns to CDMO Fujifilm to boost US manufacturing capacity

Title

Regeneron Partners with Fujifilm Diosynth in $3B, 10-Year Deal to Double U.S. Biologics Manufacturing Capacity

Regeneron Pharmaceuticals has entered into a 10-year manufacturing supply agreement valued at over $3 billion with FUJIFILM Diosynth Biotechnologies to significantly expand its U.S. biologics manufacturing capacity2 4 5.
The multi-year partnership will be anchored at Fujifilm’s new large-scale biopharmaceutical manufacturing facility in Holly Springs, North Carolina, which is set to begin operations later in 20252 5.
This agreement is expected to nearly double Regeneron’s current domestic manufacturing capability for its industry-leading biologic medicines, which treat millions of patients worldwide4 5.
The partnership is part of Regeneron’s broader strategy to onshore drug production amid industry-wide pushes to reduce reliance on overseas manufacturing and mitigate risks such as potential U.S. tariffs on pharmaceutical imports5.
The Holly Springs facility is part of Fujifilm’s ongoing $7 billion global expansion, with more than $3.2 billion already invested in the U.S. site2 5.
Technology transfer for the collaboration is already underway, though specific Regeneron drugs to be produced at the site have not yet been disclosed5.
The manufacturing boost will leverage Fujifilm’s expertise as a leading CDMO for biologics, vaccines, and advanced therapies, ensuring secure and scalable supply of Regeneron’s key products2 5.